Astellas has appointed John Demaree as vice president of oncology marketing for its Americas operations.
In his new role, Demaree will lead the promotion of in-market products, the preparation of product launches and will collaborate with Astellas’ partner organisations in the region on marketing strategy.
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Prior to joining Astellas in 2011, Demaree served as the general manager for oncology business development and alliance management at Abbott, and also brings experience from Eli Lilly and Novartis.
Mark Reisenauer, senior vice president of the oncology business unit for Astellas Americas, said: “Astellas is committed to making a difference in the lives of cancer patients through an emphasis on innovation and R&D.
“We are confident that John’s commercial experience in oncology will help us make strides in improving care for the patients we serve.”